BACKGROUND/AIMS: Carbohydrate deficient transferrin has been introduced as a marker of excessive alcohol intake. The present study was undertaken in order to measure the circulating level of carbohydrate deficient transferrin in patients with alcoholic cirrhosis and to assess arteriovenous kinetics of carbohydrate deficient transferrin in liver and kidney. METHODS/ RESULTS: The median value of serum carbohydrate deficient transferrin was 16.0 U/l in patients with alcoholic cirrhosis (n = 41), and this value was not significantly different from that of a normal control group (median 17.4 U/l, n = 55, ns). Carbohydrate deficient transferrin was significantly higher in patients with cirrhosis and high current alcohol intake than in abstaining patients (20 vs. 14 U/l, p < 0.05). Similarly, controls with a high current alcohol intake (> 50 g/day) had a significantly higher carbohydrate deficient transferrin concentration than controls with a low alcohol intake (< 10 g/day) (36 vs. 14.9 U/l, p < 0.005). No significant differences were detected between carbohydrate deficient transferrin in artery and liver vein or artery and renal vein, either in patients with alcoholic cirrhosis (n = 11) or in controls (n = 8), which indicates a slow turnover rate of carbohydrate deficient transferrin. Food ingestion did not affect the circulating level of carbohydrate deficient transferrin, and the analysis of carbohydrate deficient transferrin was almost unaffected by the presence of ethanol in plasma within the biological range (ethanol 0-100 mmol/l). CONCLUSIONS: Our results suggest that measurement of carbohydrate deficient transferrin may be used in patients with alcoholic cirrhosis. High current alcohol intake is associated with higher carbohydrate deficient transferrin levels than in those with low alcohol intake, but the overlap is substantial in patients with cirrhosis. Carbohydrate deficient transferrin has a low turnover rate in both patients with cirrhosis and normals.
BACKGROUND/AIMS: Carbohydrate deficient transferrin has been introduced as a marker of excessive alcohol intake. The present study was undertaken in order to measure the circulating level of carbohydrate deficient transferrin in patients with alcoholic cirrhosis and to assess arteriovenous kinetics of carbohydrate deficient transferrin in liver and kidney. METHODS/ RESULTS: The median value of serum carbohydrate deficient transferrin was 16.0 U/l in patients with alcoholic cirrhosis (n = 41), and this value was not significantly different from that of a normal control group (median 17.4 U/l, n = 55, ns). Carbohydrate deficient transferrin was significantly higher in patients with cirrhosis and high current alcohol intake than in abstaining patients (20 vs. 14 U/l, p < 0.05). Similarly, controls with a high current alcohol intake (> 50 g/day) had a significantly higher carbohydrate deficient transferrin concentration than controls with a low alcohol intake (< 10 g/day) (36 vs. 14.9 U/l, p < 0.005). No significant differences were detected between carbohydrate deficient transferrin in artery and liver vein or artery and renal vein, either in patients with alcoholic cirrhosis (n = 11) or in controls (n = 8), which indicates a slow turnover rate of carbohydrate deficient transferrin. Food ingestion did not affect the circulating level of carbohydrate deficient transferrin, and the analysis of carbohydrate deficient transferrin was almost unaffected by the presence of ethanol in plasma within the biological range (ethanol 0-100 mmol/l). CONCLUSIONS: Our results suggest that measurement of carbohydrate deficient transferrin may be used in patients with alcoholic cirrhosis. High current alcohol intake is associated with higher carbohydrate deficient transferrin levels than in those with low alcohol intake, but the overlap is substantial in patients with cirrhosis. Carbohydrate deficient transferrin has a low turnover rate in both patients with cirrhosis and normals.
Authors: Xiao-Ming Ou; Chandra Johnson; Deyin Lu; Shakevia Johnson; Ian A Paul; Mark C Austin; Abiye H Iyo; Jose Javier Miguel-Hidalgo; Jia Luo; Richard L Bell; Matthew Grunewald; Junming Wang; Donald B Sittman Journal: Neurotox Res Date: 2010-03-05 Impact factor: 3.911
Authors: Xiao-Ming Ou; Craig A Stockmeier; Herbert Y Meltzer; James C Overholser; George J Jurjus; Lesa Dieter; Kevin Chen; Deyin Lu; Chandra Johnson; Moussa B H Youdim; Mark C Austin; Jia Luo; Akira Sawa; Warren May; Jean C Shih Journal: Biol Psychiatry Date: 2009-12-22 Impact factor: 13.382
Authors: Jeremy W Duncan; Shakevia Johnson; Xiao Zhang; Baoying Zheng; Jia Luo; Xiao-Ming Ou; Craig A Stockmeier; Jun Ming Wang Journal: Alcohol Clin Exp Res Date: 2016-09-20 Impact factor: 3.455
Authors: Jeremy Duncan; Niping Wang; Xiao Zhang; Shakevia Johnson; Sharonda Harris; Baoying Zheng; Qinli Zhang; Grazyna Rajkowska; Jose Javier Miguel-Hidalgo; Donald Sittman; Xiao-Ming Ou; Craig A Stockmeier; Jun Ming Wang Journal: Neurotox Res Date: 2015-03-05 Impact factor: 3.911
Authors: Jeremy W Duncan; Xiao Zhang; Niping Wang; Shakevia Johnson; Sharonda Harris; Chinelo Udemgba; Xiao-Ming Ou; Moussa B Youdim; Craig A Stockmeier; Jun Ming Wang Journal: Neuropharmacology Date: 2016-01-22 Impact factor: 5.250
Authors: Xiao-Ming Ou; Deyin Lu; Chandra Johnson; Kevin Chen; Moussa B H Youdim; Grazyna Rajkowska; Jean C Shih Journal: Neurotox Res Date: 2009-05-28 Impact factor: 3.911
Authors: Kevin J Fagan; Katharine M Irvine; Brett C McWhinney; Linda M Fletcher; Leigh U Horsfall; Lambro Johnson; Peter O'Rourke; Jennifer Martin; Ian Scott; Carel J Pretorius; Jacobus P J Ungerer; Elizabeth E Powell Journal: BMC Gastroenterol Date: 2014-05-22 Impact factor: 3.067